Bristol To Overcome Sprycel Uptake “Resistance” By Encouraging Faster Switching
Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.
Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.